All In Biotech

BLA 125293 · Horizon Pharma

Krystexxa

Pegloticase · Injection · Uric Acid-specific Enzyme

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Sep 14, 2010

Approved uses

2

Original approval plus efficacy supplements

Registered trials

22

4 Phase 3, 1 recruiting

FAERS reports

3,875

1,895 serious, 135 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS and INFUSION REACTIONS, G6PD DEFICIENCY ASSOCIATED HEMOLYSIS and METHEMOGLOBINEMIA Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. ( 5.1 , 5.2 ) Anaphylaxis may occur with any infusion, and generally manifests within 2 hours of the infusion. However, delayed hypersensitivity reactions have also been reported. ( 5.1 ) KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. ( 5.1 , 5.2 ) Premedicate with antihistamines and corticosteroids and closely monitor for anaphylaxis for an appropriate period of time after administration of KRYSTEXXA. ( 5.1 , 5.2 ) Monitor serum uric acid levels prior to each infusion and discontinue treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are...

What it is approved for

From the label in effect Nov 2, 2026.

KRYSTEXXA ® (pegloticase) is indicated, for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. KRYSTEXXA ® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. ( 1 ) Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. ( 1 ) Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Mechanism: KRYSTEXXA is a uric acid specific enzyme which is a recombinant uricase and achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water-soluble purine metabolite; it is readily eliminated, primarily by renal excretion.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KRYSTEXXA · PEGLOTICASE 8MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegloticase" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • gout575
  • blood uric acid increased417
  • infusion related reaction367
  • therapeutic response decreased240
  • dyspnoea184
  • drug ineffective155
  • nausea150
  • urticaria150
  • off label use138
  • pruritus138
  • rash133
  • dizziness117

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201152
201278
201398
201457
201548
201696
2017104
2018264
2019384
2020240
2021101
2022351
2023426
2024582
2025473
2026521

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Krystexxa (PEGloticase)

2024 spending

$212M

Beneficiaries

662

4,801 claims

Per beneficiary

$320,769

$28,898.90 per unit

View as table
YearSpending
2020$49,727,178
2021$68,263,090
2022$123,038,866
2023$178,838,011
2024$212,349,150

Part B: Krystexxa (Pegloticase) · HCPCS J2507

2024 spending

$283M

Beneficiaries

1,097

10,614 claims

Per beneficiary

$257,821

2024 ASP limit $3,423.05 per unit

View as table
YearSpending
2020$142,198,168
2021$160,197,749
2022$201,220,453
2023$246,712,915
2024$282,830,140

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 34 on PubMed

Sponsor: Amgen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.